Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Peru will likely create Pacific Ocean reserve in early 2019 -govt

2018-07-09 reuters
LIMA (Reuters) - Peruvian President Martin Vizcarra’s government is planning to create an ocean reserve in the first quarter to protect feeding and breeding grounds for humpback whales and other marine species, the environment minister said on Monday.
KAR KRNGY KRNGF

0
PXP Energy trims Q1 net loss

2018-05-10 bworldonline
PXP Energy Corp. trimmed its losses to P3.7 million in the first quarter, the company said on Thursday, in part because of higher petroleum revenues resulting from an improvement in the price of crude oil during the period.
KAR TLW KRNGY KRNGF

0
[Press] Tullow Oil: AGM Trading Update

2018-04-25 oilvoice
25 April 2018 – Tullow Oil plc (Tullow) issues the following Trading Update for the period 1 January to 25 April 2018. This statement is issued in advance of the Group's Annual General Meeting (AGM) which is being held at Tullow Oil plc, Building 9 Chiswick Park, London, W4 5XT at 12pm today. The Group will announce its Trading Statement and Operational Update on 27 June 2018 and Half Year Results will be announced on 25 July 2018.
KAR TLW KRNGY KRNGF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ASX:KAR / KAROON GAS AUSTRALIA LIMITED on message board site Silicon Investor.

Hewlett Packard Enterprise (HPE) Hewlett-Packard (HPQ)
HWP -- Hewlett Packard Transkaryotic(tktx)
ENVK - Envirokare Tech Inc. Karl Rove: A mastermind or a liability for George Bush
Martial Arts, Karate KARATE MOVIE STARS VS. BASHERS ! who would win?
Karma is as Karma Does PBSC - Packard BioScience